Logo 1 Logo 2

Clinical Trial Details

Trial ID: L1718
Source ID: NCT00077597
Associated Drug: Epoetin
Title: A Study of Mircera for the Treatment of Anemia in Dialysis Patients
Acronym:
Status: COMPLETED
Study Results: NO
Results:
Conditions: Anemia
Interventions: DRUG: epoetin|DRUG: methoxy polyethylene glycol-epoetin beta [Mircera]
Outcome Measures: Primary: Hemoglobin response rate, Weeks 1-24 | Secondary: Hb over time, time to target Hb response, incidence of RBC transfusions. Vital signs, ECG, AEs, laboratory values\n, Throughout study
Sponsor/Collaborators: Sponsor: Hoffmann-La Roche
Gender: ALL
Age: ADULT, OLDER_ADULT
Phases: PHASE3
Enrollment: 182
Study Type: INTERVENTIONAL
Study Designs: Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT
Start Date: 2004-02
Completion Date: 2006-06
Results First Posted:
Last Update Posted: 2016-11-02
Locations: Davis, California, 95616, United States|Lakewood, Colorado, 80260, United States|Atlanta, Georgia, 30342, United States|Augusta, Georgia, 30901, United States|New Orleans, Louisiana, 70112, United States|Boston, Massachusetts, 02115, United States|Springfield, Massachusetts, 01107, United States|Detroit, Michigan, 48202-2689, United States|Mineola, New York, 11501, United States|New York, New York, 10128, United States|Toledo, Ohio, 43606, United States|Houston, Texas, 77054, United States|Burlington, Vermont, 05401, United States|Norfolk, Virginia, 23507-1901, United States|Curitiba, 81050-090, Brazil|Ribeirão Preto, 14025-170, Brazil|Sao Paulo, 01307-001, Brazil|Sao Paulo, 04039-000, Brazil|Calgary, Alberta, T2N 2T9, Canada|Vancouver, British Columbia, V5Z 1M9, Canada|Winnipeg, Manitoba, R3A 1R9, Canada|St. John's, Newfoundland and Labrador, A1B 3V6, Canada|Kingston, Ontario, K7L 3N6, Canada|London, Ontario, N6A 5A5, Canada|Toronto, Ontario, M5G 2C4, Canada|Montreal, Quebec, H3A 1A1, Canada|Saskatoon, Saskatchewan, S7K 1N4, Canada|Liberec, 460 63, Czech Republic|Praha, 169 00, Czech Republic|Usti Nad Labem, 401 13, Czech Republic|Alexandroupolis, 68100, Greece|Larissa, 41 110, Greece|Nikea, 18354, Greece|Thessaloniki, 54629, Greece|Bergen, 5021, Norway|Oslo, 0407, Norway|Gdansk, 80-211, Poland|Gdynia, 81-519, Poland|Krakow, 31-501, Poland|Lodz, 90-153, Poland|Poznan, 60-355, Poland|Szczecin, 70-111, Poland|Wolomin, 05-200, Poland|Wroclaw, 50-417, Poland|Moscow, 123182, Russian Federation|Moscow, 125101, Russian Federation|Moscow, 129110, Russian Federation|St Petersburg, 195067, Russian Federation|St Petersburg, 197089, Russian Federation|Johannesburg, 2193, South Africa|Soweto, South Africa|Bilbao, 48013, Spain|Santander, 39008, Spain|Karlstad, 65185, Sweden|Lausanne, 1011, Switzerland|Bangkok, 10700, Thailand|Bangkok, Thailand|Chiang Mai, 50200, Thailand|Chonburi, Thailand
URL: https://clinicaltrials.gov/show/NCT00077597

Drug ID Drug Name Type DrugBank ID Targets Category Latest Progress